Particle.news
Download on the App Store
3 ARTICLES
·
last mo.

New Studies Link GLP-1 Drugs Like Semaglutide to Reduced Dementia Risk in Diabetics

Research published in JAMA Neurology highlights a significant association between GLP-1 receptor agonists and lower Alzheimer’s risk, with semaglutide showing particular promise.

Image
Image

Overview

  • Two studies published in JAMA Neurology analyzed the effects of GLP-1 receptor agonists (GLP-1RAs) and SGLT-2 inhibitors on dementia risk in type 2 diabetes patients.
  • A retrospective study of nearly 400,000 patients and a meta-analysis of 26 clinical trials found GLP-1RAs significantly reduced Alzheimer’s disease and related dementias (ADRD) risk.
  • Semaglutide, a GLP-1RA marketed under names like Ozempic and Wegovy, demonstrated especially strong potential in lowering dementia risk compared to other drugs.
  • Researchers suggest the neuroprotective effects may stem from reduced neuroinflammation and improved metabolic health, though mechanisms remain under investigation.
  • Experts emphasize the need for prospective trials to confirm causality and explore whether these benefits extend to non-diabetic populations.